MOG抗体相关疾病、多发性硬化及AQP4-IgG阳性视神经脊髓炎谱系疾病中的瘤样脱髓鞘
本研究回顾性分析了MOGAD、AQP4+NMOSD及MS患者的瘤样脑病灶,发现瘤样病灶在MOGAD中更常见(22% vs 5%),但不影响复发和步态辅助需求;MOGAD的临床、MRI和脑脊液特征与MS不同,而与AQP4+NMOSD相似,但病灶消退更常见。
要点
- 瘤样病灶在MOGAD中占22%,高于AQP4+NMOSD的5%。
- MOGAD瘤样病灶患者复发风险和步态辅助需求与非瘤样MOGAD相似。
- MOGAD的MRI特征与MS不同,而与AQP4+NMOSD相似,但病灶消退更常见。
核心结论
- 瘤样病灶在MOGAD中常见,但与更差预后无关;其临床、MRI和脑脊液特征不同于瘤样MS,而与瘤样AQP4+NMOSD相似,但病灶消退更常见于MOGAD。
研究设计与样本
- 回顾性研究,从Mayo Clinic数据库检索194例MOGAD和359例AQP4+NMOSD患者,纳入MRI上至少1个瘤样脑病灶(最大横径≥2 cm)者,并通过病历链接系统识别瘤样MS患者。
主要发现
- 瘤样病灶在MOGAD中占43/194(22%),高于AQP4+NMOSD的16/359(5%),p < 0.001。
- 瘤样MOGAD与非瘤样MOGAD的复发风险和步态辅助需求相似。
- MOGAD较MS更常见头痛(18/43 [42%] vs 10/49 [20%],p = 0.03)和嗜睡(12/43 [28%] vs 2/49 [4%],p = 0.003),嗜睡在MOGAD也较AQP4+NMOSD更常见(0/16 [0%],p = 0.02)。
- 周边T2低信号环、T1低信号、扩散受限(尤其弧形)、环形强化和Baló样或囊性表现更支持MS而非MOGAD(p ≤ 0.001);AQP4+NMOSD扩散受限比例高于MOGAD(10/15 [67%] vs 11/42 [26%],p = 0.005)。
- 脑脊液寡克隆带阳性在MOGAD中较少(2/37 [5%] vs MS 30/43 [70%],p < 0.001),白细胞计数中位数在MOGAD高于MS(33 vs 6 cells/μL,p < 0.001)。
关键数值与推荐
- MOGAD诊断的独立预测因素包括嗜睡/头痛、无T2低信号环、无T1低信号和无扩散受限(Nagelkerke R² = 0.67)。
- 瘤样病灶消退在MOGAD中较MS或AQP4+NMOSD更常见,并改善模型性能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Studies on tumefactive brain lesions in myelin oligodendrocyte glycoprotein-immunoglobulin G (IgG)-associated disease (MOGAD) are lacking. We sought to characterize the frequency clinical, laboratory, and MRI features of these lesions in MOGAD and compare them with those in multiple sclerosis (MS) and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). METHODS: We retrospectively searched 194 patients with MOGAD and 359 patients with AQP4+NMOSD with clinical/MRI details available from the Mayo Clinic databases and included those with ≥1 tumefactive brain lesion (maximum transverse diameter ≥2 cm) on MRI. Patients with tumefactive MS were identified using the Mayo Clinic medical record linkage system. Binary multivariable stepwise logistic regression identified independent predictors of MOGAD diagnosis; Cox proportional regression models were used to assess the risk of relapsing disease and gait aid in patients with tumefactive MOGAD vs those with nontumefactive MOGAD. RESULTS: We included 108 patients with tumefactive demyelination (MOGAD = 43; AQP4+NMOSD = 16; and MS = 49). Tumefactive lesions were more frequent among those with MOGAD (43/194 [22%]) than among those with AQP4+NMOSD (16/359 [5%], p < 0.001). Risk of relapse and need for gait aid were similar in tumefactive and nontumefactive MOGAD. Clinical features more frequent in MOGAD than in MS included headache (18/43 [42%] vs 10/49 [20%]; p = 0.03) and somnolence (12/43 [28%] vs 2/49 [4%]; p = 0.003), the latter also more frequent than in AQP4+NMOSD (0/16 [0%]; p = 0.02). The presence of peripheral T2-hypointense rim, T1-hypointensity, diffusion restriction (particularly an arc pattern), ring enhancement, and Baló-like or cystic appearance favored MS over MOGAD (p ≤ 0.001). MRI features were broadly similar in MOGAD and AQP4+NMOSD, except for more frequent diffusion restriction in AQP4+NMOSD (10/15 [67%]) than in MOGAD (11/42 [26%], p = 0.005). CSF analysis revealed less frequent positive oligoclonal bands in MOGAD (2/37 [5%]) than in MS (30/43 [70%], p < 0.001) and higher median white cell count in MOGAD than in MS (33 vs 6 cells/μL, p < 0.001). At baseline, independent predictors of MOGAD diagnosis were the presence of somnolence/headache, absence of T2-hypointense rim, lack of T1-hypointensity, and no diffusion restriction (Nagelkerke R 2 = 0.67). Tumefactive lesion resolution was more common in MOGAD than in MS or AQP4+NMOSD and improved model performance. DISCUSSION: Tumefactive lesions are frequent in MOGAD but not associated with a worse prognosis. The clinical, MRI, and CSF attributes of tumefactive MOGAD differ from those of tumefactive MS and are more similar to those of tumefactive AQP4+NMOSD with the exception of lesion resolution, which favors MOGAD.
引用
- Cacciaguerra L, Morris P, Tobin WO, et al. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. Neurology. 2023. PMID: 36690455. doi:10.1212/WNL.0000000000206820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。